VIDEO: Trulance significantly improves CIC, IBS-C abdominal symptoms
Click Here to Manage Email Alerts
In this video exclusive, Gregory S. Sayuk, MD, MPH, discussed the impact of Trulance on pain, discomfort and bloating in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation.
Sayuk, associate professor of medicine and psychiatry and associate director of the fellowship training program in the division of gastroenterology at Washington University School of Medicine and gastroenterologist at the John Cochran Veterans Affairs Medical Center, both in St. Louis, presented the research at the ACG Annual Scientific Meeting.
There were 1,762 patients with CIC and 1,453 patients with IBS-C randomly assigned to receive Trulance (plecanatide, Salix Pharmaceuticals) 3 mg or placebo for 12 weeks. Sayuk and colleagues performed a subgroup analysis of patients who reported severe bloating, pain and discomfort.
“There were great percentages of the IBS-C patients that were treated with plecanatide that had a greater than 30% improvement in these abdominal symptoms that extended to the patients that had severe symptoms,” Sayuk said. “In the CIC symptoms, total response across all these symptoms were statistically greater but when we looked at severe patients, we saw a numerical improvement but not statistically significant improvements.”
Collapse
Sayuk GS. Poster: P2482. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021; Las Vegas (hybrid meeting).
Click Here to Manage Email Alerts